P. Yates

发表

The receptor‐binding and membrane‐fusion properties of influenza virus variants selected using anti‐haemagglutinin monoclonal antibodies.

J. Skehel, D. Wiley, J. Paulson, 1987, The EMBO journal.

Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.

Janet Daly, Margaret Tisdale, J. Daly, 2006, The Journal of antimicrobial chemotherapy.

The haemagglutinins of influenza A (H1N1) viruses in the ‘O’ or ‘D’ phases exhibit biological and antigenic differences

J. Oxford, K. Zakrzewska, P. Yates, 1993, Epidemiology and Infection.

Direct isolation in eggs of influenza A (H1N1) and B viruses with haemagglutinins of different antigenic and amino acid composition.

J. Oxford, P. Yates, G. Schild, 1991, The Journal of general virology.

Serological studies with influenza A(H1N1) viruses cultivated in eggs or in a canine kidney cell line (MDCK).

J. Oxford, R. Webster, J. Bates, 1987, Bulletin of the World Health Organization.

Protein and nucleic acid analysis of influenza B viruses isolated in Italy in 1984

J. Oxford, M. Castrucci, I. Donatelli, 1989, Journal of medical virology.

Evaluation of Safety and Efficacy of Intravenous Zanamivir in the Treatment of Hospitalized Japanese Patients with Influenza: An Open-Label, Single-Arm Study

P. Yates, A. Watanabe, T. Soutome, 2015, Antiviral therapy.

Safety and Pharmacokinetics of Intravenous Zanamivir Treatment in Hospitalized Adults With In ﬂ uenza: An Open-label, Multicenter, Single-Arm, Phase II Study

D. Brealey, J. Lorente, P. Yates, 2014 .

Phenotypic and genotypic analysis of influenza viruses isolated from adult subjects during a phase II study of intravenous zanamivir in hospitalised subjects.

P. Yates, Nalini A. L. Mehta, Henry H. Zhao, 2016, Antiviral research.

Virus Susceptibility Analyses from a Phase IV Clinical Trial of Inhaled Zanamivir Treatment in Children Infected with Influenza

P. Yates, M. Tisdale, Joseph H Horton, 2013, Antimicrobial Agents and Chemotherapy.

Efficacy and Safety of Danirixin (GSK1325756) Co-administered With Standard-of-Care Antiviral (Oseltamivir): A Phase 2b, Global, Randomized Study of Adults Hospitalized With Influenza

A. Madan, M. McClain, P. Yates, 2019, Open forum infectious diseases.

Lessons from resistance analysis in clinical trials of IV zanamivir.

P. Yates, Helen A Watson, Nalini A. L. Mehta, 2023, Virus research.

Safety and Pharmacokinetics of Intravenous Zanamivir Treatment in Hospitalized Adults With Influenza: An Open-label, Multicenter, Single-Arm, Phase II Study

D. Brealey, J. Lorente, P. Yates, 2013, The Journal of infectious diseases.

Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial

M. Yuen, J. Jang, Jung-Hwan Yoon, 2021, Nature Medicine.

Nucleotide sequence at position 1081 of the hemagglutinin-neuraminidase gene in the mumps Urabe vaccine strain.

P. Yates, P. Minor, M. Afzal, 1998, The Journal of infectious diseases.

Antigenic and genetic variation of the HN protein of mumps virus strains.

P. Yates, P. Minor, M. Afzal, 1996, The Journal of general virology.

Matrix protein gene sequence of vaccine and vaccine-associated strains of mumps virus.

P. Yates, P. Minor, M. Afzal, 1994, The Journal of general virology.

Differentiation of vaccine and wild mumps viruses using the polymerase chain reaction and dideoxynucleotide sequencing.

P. Yates, P. Minor, T. Forsey, 1990, The Journal of general virology.

In Vitro Antiviral Activity of the Novel, Tyrosyl-Based Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor Brecanavir (GW640385) in Combination with Other Antiretrovirals and against a Panel of Protease Inhibitor-Resistant HIV

M. Hanlon, E. Furfine, P. Yates, 2007, Antimicrobial Agents and Chemotherapy.

A hybridoma cell line secreting antibody to poliovirus type 3 D-antigen: detection in virus harvest of two D-antigen populations.

P. Yates, G. Schild, P. Minor, 1981, Journal of General Virology.

GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks

R. Elston, W. Snowden, P. Yates, 2004, AIDS.

Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Clinical Effect of Danirixin in Adults With Acute, Uncomplicated Influenza

E. Kerwin, A. Madan, P. Yates, 2019, Open forum infectious diseases.

Experimental infection of ponies with equine influenza A2 (H3N8) virus strains of different pathogenicity elicits varying interferon and interleukin-6 responses.

P. Yates, L. Fuxler, E. Wattrang, 2003, Viral immunology.

In Vitro Development of Resistance to Human Immunodeficiency Virus Protease Inhibitor GW640385

R. Elston, P. Yates, L. Boone, 2006, Antimicrobial Agents and Chemotherapy.

The antigenic structure of a human influenza A (H1N1) virus isolate grown exclusively in MDCK cells.

P. Yates, J. Robertson, J. Bootman, 1990, The Journal of general virology.

Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial.

P. Yates, F. Marty, D. Shortino, 2017, The Lancet. Respiratory medicine.

Intravenous Zanamivir in Hospitalized Patients With Influenza

R. DeBiasi, P. Yates, D. Shortino, 2017, Pediatrics.

Population Pharmacokinetic/Pharmacodynamic Analysis of Intravenous Zanamivir in Healthy Adults and Hospitalized Adult and Pediatric Subjects With Influenza

P. Yates, A. Barth, Helen A Watson, 2019, Clinical and translational science.

Efficacy and Safety of Danirixin (GSK1325756) Co-administered With Standard-of-Care Antiviral (Oseltamivir): A Phase 2b, Global, Randomized Study of Adults Hospitalized With Influenza

A. Madan, M. McClain, P. Yates, 2019, Open forum infectious diseases.